Cargando…
SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools
OBJECTIVE: This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test. STUDY DESIGN AND SETTING: We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which cond...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760838/ https://www.ncbi.nlm.nih.gov/pubmed/35041972 http://dx.doi.org/10.1016/j.jclinepi.2022.01.002 |
_version_ | 1784633407136858112 |
---|---|
author | Polechová, Jitka Johnson, Kory D. Payne, Pavel Crozier, Alex Beiglböck, Mathias Plevka, Pavel Schernhammer, Eva |
author_facet | Polechová, Jitka Johnson, Kory D. Payne, Pavel Crozier, Alex Beiglböck, Mathias Plevka, Pavel Schernhammer, Eva |
author_sort | Polechová, Jitka |
collection | PubMed |
description | OBJECTIVE: This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test. STUDY DESIGN AND SETTING: We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children. RESULTS: Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort. CONCLUSION: Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-8760838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87608382022-01-18 SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools Polechová, Jitka Johnson, Kory D. Payne, Pavel Crozier, Alex Beiglböck, Mathias Plevka, Pavel Schernhammer, Eva J Clin Epidemiol Covid-Series OBJECTIVE: This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test. STUDY DESIGN AND SETTING: We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children. RESULTS: Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort. CONCLUSION: Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic. The Authors. Published by Elsevier Inc. 2022-05 2022-01-15 /pmc/articles/PMC8760838/ /pubmed/35041972 http://dx.doi.org/10.1016/j.jclinepi.2022.01.002 Text en © 2022 The Authors. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Covid-Series Polechová, Jitka Johnson, Kory D. Payne, Pavel Crozier, Alex Beiglböck, Mathias Plevka, Pavel Schernhammer, Eva SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools |
title | SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools |
title_full | SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools |
title_fullStr | SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools |
title_full_unstemmed | SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools |
title_short | SARS-CoV-2 rapid antigen tests provide benefits for epidemic control – observations from Austrian schools |
title_sort | sars-cov-2 rapid antigen tests provide benefits for epidemic control – observations from austrian schools |
topic | Covid-Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760838/ https://www.ncbi.nlm.nih.gov/pubmed/35041972 http://dx.doi.org/10.1016/j.jclinepi.2022.01.002 |
work_keys_str_mv | AT polechovajitka sarscov2rapidantigentestsprovidebenefitsforepidemiccontrolobservationsfromaustrianschools AT johnsonkoryd sarscov2rapidantigentestsprovidebenefitsforepidemiccontrolobservationsfromaustrianschools AT paynepavel sarscov2rapidantigentestsprovidebenefitsforepidemiccontrolobservationsfromaustrianschools AT crozieralex sarscov2rapidantigentestsprovidebenefitsforepidemiccontrolobservationsfromaustrianschools AT beiglbockmathias sarscov2rapidantigentestsprovidebenefitsforepidemiccontrolobservationsfromaustrianschools AT plevkapavel sarscov2rapidantigentestsprovidebenefitsforepidemiccontrolobservationsfromaustrianschools AT schernhammereva sarscov2rapidantigentestsprovidebenefitsforepidemiccontrolobservationsfromaustrianschools |